TABLE 4.
Rationale for Prescription of Specific Antifungal Agents
| Agent, n (%) | Prophylaxis (n = 752) | Treatment | Total (n = 1227)* | ||
|---|---|---|---|---|---|
| Empiric (n = 189) | Preemptive (n = 172) | Targeted (n = 114) | |||
| L-AmB | 275 (36.6) | 89 (47.1) | 84 (48.8) | 19 (16.7) | 467 |
| Itraconazole | 260 (34.6) | 1 (0.5) | 1 (0.6) | 3 (2.6) | 265 |
| Voriconazole | 48 (6.4) | 18 (9.5) | 30 (17.4) | 14 (12.3) | 110 |
| Posaconazole | 47 (6.2) | 9 (4.8) | 7 (4.1) | 8 (7.0) | 71 |
| Isavuconazole | 0 | 0 | 0 | 1 (0.9) | 1 |
| Fluconazole | 85 (11.3) | 46 (24.3) | 13 (7.6) | 49 (43.0) | 193 |
| Micafungin | 26 (3.4) | 11 (5.8) | 28 (16.3) | 3 (2.6) | 68 |
| Caspofungin | 8 (1.1) | 10 (5.3) | 7 (4.1) | 11 (9.6) | 36 |
| Anidulafungin | 0 | 0 | 0 | 1 (0.9) | 1 |
| Flucytosine | 0 | 0 | 0 | 5 (4.4) | 5 |
| Other AmB | 3 (0.4) | 5 (2.6) | 2 (1.2) | 0 | 10 |
*Total prescriptions 1258, from those, 1227 with full information on rational.
Other AmB: amphotericin B deoxycholate and lipids formulations of amphotericin B.